|1.||Miller, Duane D: 6 articles (10/2010 - 04/2005)|
|2.||Dalton, James T: 6 articles (10/2010 - 04/2005)|
|3.||Cravatt, Benjamin F: 5 articles (01/2014 - 06/2004)|
|4.||Lichtman, Aron H: 4 articles (01/2012 - 06/2004)|
|5.||Csuk, René: 3 articles (12/2015 - 01/2013)|
|6.||Lu, Yan: 3 articles (10/2010 - 08/2007)|
|7.||Hurh, Eunju: 3 articles (10/2010 - 04/2005)|
|8.||Yagen, Boris: 3 articles (05/2010 - 12/2005)|
|9.||Bialer, Meir: 3 articles (05/2010 - 12/2005)|
|10.||Li, Wei: 3 articles (06/2008 - 03/2007)|
06/01/1984 - "For those N-alkyl amides tested, 4-amino-N- amylbenzamide (6) was the most potent against maximal electroshock seizures (MES): ED50 = 42.98 mg/kg; however, the N- cyclohexylbenzamide (8) showed the greatest protective index (PI = TD50/ED50), 2.8. "
04/01/1999 - "The amides (12-14) showed protection against MES and/or scMet seizures in mice. "
11/01/1995 - "2-(4-Phenylpiperazine)-4-phthalimidobutyric acid and three N-substituted amides of this acid displaced protection against MES and scMet-induced seizures."
06/01/2004 - "Amino acid amides (AAA) were prepared and evaluated in seizure models. "
03/01/1996 - "All obtained amides as well as one intermediate (8) were evaluated in the maximal electroshock seizure (MES) test, the subcutaneous Metrazol seizure threshold (sc Met) test and the rotorod neurotoxicity (Tox) test in mice. "
09/01/2005 - "Targeted lipidomics: fatty acid amides and pain modulation."
09/01/2005 - "Many fatty acid amides appear to play a role in pain and inflammation. "
11/26/2009 - "Among these, two amide and two urea derivatives of 1 showed the highest potency as antineuropathic pain compounds, with ED(50) values of 49 and 51 mg/kg for the amides (19 and 20) and 49 and 74 mg/kg for the urea derivatives (29 and 33), respectively. "
01/01/2005 - "The role of endocannabinoids and related fatty acid amides that are implicated in endogenous mechanisms for pain suppression are discussed. "
12/01/2009 - "Pain and beyond: fatty acid amides and fatty acid amide hydrolase inhibitors in cardiovascular and metabolic diseases."
10/30/1992 - "The presence of more than one basic group in the amidic chain enhanced the in vitro activity of some TD-amides against Gram-negative bacteria; two of these derivatives were also effective in vivo against Escherichia coli septicemia in the mouse. "
11/01/1989 - "In experimental Streptococcus pyogenes septicemia in the mouse, some basic amides were more active than the parent teicoplanins when administered subcutaneously. "
|4.||Neuralgia (Stump Neuralgia)
10/15/2014 - "Further study on Piper amides is warranted, particularly whether side chain length affects the ability to overcome the MDR cancer phenotype."
05/15/2015 - "The correction of CEST effects alters the contrast significantly: after correction, the CEST effect of amides does not show significant contrast between contrast enhancing tumor regions and normal tissue, whereas NOE drops significantly in the tumor area. "
01/15/2015 - "In the work, the in vitro antiproliferative activity of a series of synthetic fatty acid amides were investigated in seven cancer cell lines. "
11/24/2014 - "Synthesis and preliminary mechanistic evaluation of 5-(p-tolyl)-1-(quinolin-2-yl)pyrazole-3-carboxylic acid amides with potent antiproliferative activity on human cancer cell lines."
07/01/2014 - "The molecular size, shape and ability for electrostatic interaction are useful parameters for estimating the tumor selectivity of phenylpropanoid amides."
|1.||gamma-Aminobutyric Acid (GABA)
|2.||Valproic Acid (Valproate, Semisodium)
|3.||Homologous Transplantation (Allograft)
|4.||Heterologous Transplantation (Xenotransplantation)